ASXC - Asensus Surgical, Inc. Stock Price, Fair Value and News

0.26USD0.00 (0.00%)Delayed

Market Summary

USD0.260.00

Delayed

0.00%

ASXC Stock Price

View Fullscreen

ASXC RSI Chart

ASXC Valuation

Market Cap

70.8M

Price/Earnings (Trailing)

-0.9

Price/Sales (Trailing)

8.12

EV/EBITDA

-0.83

Price/Free Cashflow

-1.16

ASXC Price/Sales (Trailing)

ASXC Profitability

Operating Margin

8.90%

EBT Margin

-899.16%

Return on Equity

-604.36%

Return on Assets

-192.86%

Free Cashflow Yield

-85.99%

ASXC Fundamentals

ASXC Revenue

Revenue (TTM)

8.7M

Rev. Growth (Yr)

15.06%

Rev. Growth (Qtr)

-79.32%

ASXC Earnings

Earnings (TTM)

-78.7M

Earnings Growth (Yr)

-1.26%

Earnings Growth (Qtr)

-30.53%

Breaking Down ASXC Revenue

Last 7 days

-3.7%

Last 90 days

-13.3%

Trailing 12 Months

-54.6%

How does ASXC drawdown profile look like?

ASXC Financial Health

Current Ratio

ASXC Investor Care

Shares Dilution (1Y)

13.72%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	8.7M	0	0	0
2023	7.0M	7.1M	5.6M	8.6M
2022	7.2M	7.1M	7.1M	7.1M
2021	4.7M	5.1M	6.9M	8.2M
2020	7.0M	4.0M	2.8M	3.2M
2019	21.5M	18.8M	15.4M	8.5M
2018	9.9M	14.7M	20.0M	24.1M
2017	3.6M	5.0M	3.8M	7.1M
2016	0	0	1.8M	1.7M
2014	1.2M	787.0K	486.0K	401.0K
2013	2.0M	1.8M	1.6M	1.4M
2012	0	0	0	2.1M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Asensus Surgical, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 21, 2024	shameze rampertab	sold (taxes)	-10,909	0.25	-43,638	evp, chief financial officer
Apr 21, 2024	shameze rampertab	acquired	-	-	81,521	evp, chief financial officer
Apr 21, 2024	fernando anthony c. j.	sold (taxes)	-29,857	0.25	-119,429	president and ceo
Apr 21, 2024	fernando anthony c. j.	acquired	-	-	271,739	president and ceo
Feb 04, 2024	fernando anthony c. j.	acquired	-	-	1,042,770	president and ceo
Feb 04, 2024	shameze rampertab	sold (taxes)	-40,599	0.27	-150,367	evp, chief financial officer
Feb 04, 2024	fernando anthony c. j.	sold (taxes)	-130,834	0.27	-484,572	president and ceo
Feb 04, 2024	shameze rampertab	acquired	-	-	280,909	evp, chief financial officer
Dec 14, 2023	starling william n jr	bought	5,077	0.28	18,134	-
Dec 14, 2023	starling william n jr	sold	-5,077	0.28	-18,134	-

Which funds bought or sold ASXC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	unchanged	-	-95.00	248	-%
May 16, 2024	JANE STREET GROUP, LLC	added	464	46,681	61,873	-%
May 16, 2024	B. Riley Wealth Advisors, Inc.	reduced	-42.05	-4,346	4,186	-%
May 16, 2024	FSA Wealth Management LLC	unchanged	-	53.00	53.00	-%
May 15, 2024	Royal Bank of Canada	added	8.38	-	-	-%
May 15, 2024	MASTERS CAPITAL MANAGEMENT LLC	unchanged	-	-177,800	460,000	0.02%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	added	414	208	285	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-16.34	-33,758	51,356	-%
May 15, 2024	GTS SECURITIES LLC	sold off	-100	-10,017	-	-%
May 15, 2024	UNITED CAPITAL FINANCIAL ADVISORS, LLC	new	-	3,680	3,680	-%

Are Funds Buying or Selling ASXC?

Are funds buying ASXC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ASXC

No. of Funds

Unveiling Asensus Surgical, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 20, 2023	state street corp	0.35%	817,129	SC 13G/A
Jul 08, 2022	blackrock inc.	1.6%	3,684,318	SC 13G
Feb 10, 2022	state street corp	5.42%	12,703,273	SC 13G
Feb 04, 2022	blackrock inc.	6.7%	15,793,991	SC 13G

Recent SEC filings of Asensus Surgical, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 15, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Apr 29, 2024	10-K/A	Annual Report
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 03, 2024	8-K	Current Report
Mar 25, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report

Peers (Alternatives to Asensus Surgical, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Asensus Surgical, Inc. News

Latest updates

Asensus Surgical, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-79.3%	1,123,000	5,431,000	1,089,000	1,081,000	976,000	2,464,000	2,563,000	994,000	1,066,000	2,476,000	2,571,000	1,102,000	2,083,000	1,106,500	814,000	655,000	600,000	687,000	2,024,000	3,639,000	2,181,000
Gross Profit	-265.8%	-1,933,000	1,166,000	-1,780,000	-1,993,000	-1,971,000	166,000	-1,841,000	-1,353,000	-757,000	189,000	-779,000	-1,245,000	-1,029,000	514,000	-609,000	-758,000	-1,138,000	-10,195,000	-1,422,000	-297,000	-286,000
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16,014,000	2,110,000	96,427,000	22,197,000	21,640,000
Operating Expenses	32.3%	22,701,000	17,164,000	18,479,000	18,870,000	20,377,000	18,293,000	17,191,000	18,214,000	18,196,000	15,873,000	16,659,000	14,839,000	14,384,000	14,222,500	14,553,000	13,608,000	16,014,000	10,245,500	96,427,000	22,197,000	-
S&GA Expenses	-3.7%	3,642,000	3,781,000	4,138,000	4,449,000	4,553,000	3,820,000	3,615,000	3,602,000	3,719,000	3,229,000	3,551,000	3,562,000	3,053,000	2,773,500	3,136,000	2,901,000	4,253,000	5,589,000	6,883,000	7,868,000	7,674,000
R&D Expenses	-6.1%	8,091,000	8,614,000	9,290,000	8,980,000	10,139,000	8,520,000	6,741,000	7,253,000	6,428,000	6,575,000	4,469,000	4,089,000	4,215,000	3,755,500	4,673,000	4,257,000	3,934,000	4,634,000	5,884,000	6,295,000	5,655,000
EBITDA Margin	1.3%	-8.62	-8.73	-13.47	-10.74	-10.69	-10.08	-9.78	-9.36	-8.37	-7.16	-8.32	-11.01	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-30,000	99,000	141,000	200,000	293,000	65,000	5,000	7,000	19,000	-	-	-	200,000	1,230,000	1,061,000	1,116,000
Income Taxes	-74.2%	46,000	178,500	57,000	-12,000	90,000	94,000	55,000	85,000	84,000	229,000	32,000	2,000	-38,000	-130,000	2,000	-691,000	-697,000	-575,000	-1,070,000	-869,000	-610,000
Earnings Before Taxes	-31.6%	-22,451,000	-17,057,000	-18,261,000	-20,674,000	-22,127,000	-17,796,000	-18,869,000	-19,534,000	-19,044,000	-15,652,000	-16,037,000	-13,170,000	-17,378,000	-13,921,500	-15,080,000	-14,531,000	-17,295,000	-14,308,000	-98,841,000	-21,040,000	-23,135,000
EBT Margin	1.3%	-8.99	-9.11	-14.06	-11.22	-11.19	-10.62	-10.30	-9.89	-8.86	-7.56	-8.82	-11.66	-	-	-	-	-	-	-	-	-
Net Income	-30.5%	-22,497,000	-17,235,000	-18,318,000	-20,662,000	-22,218,000	-17,890,000	-18,924,000	-19,619,000	-19,128,000	-15,881,000	-16,069,000	-13,172,000	-17,340,000	-13,791,500	-15,082,000	-13,840,000	-16,598,000	-13,733,000	-97,771,000	-20,171,000	-22,525,000
Net Income Margin	1.3%	-9.02	-9.14	-14.10	-11.25	-11.24	-10.66	-10.36	-9.95	-8.91	-7.59	-8.80	-11.63	-	-	-	-	-	-	-	-	-
Free Cashflow	-4.2%	-14,008,000	-13,447,000	-15,371,000	-18,058,000	-17,312,000	-14,428,000	-15,115,000	-14,484,000	-16,189,000	-13,702,000	-9,140,000	-8,553,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-30.9%	41.00	59.00	71.00	78.00	97.00	116	129	147	167	186	200	212	224	78.00	80.00	76.00	84.00	75.00	98.00	203	217
Current Assets	-47.1%	19.00	36.00	46.00	55.00	72.00	87.00	104	109	119	113	135	174	182	34.00	38.00	34.00	40.00	28.00	47.00	69.00	82.00
Cash Equivalents	-50.4%	8.00	17.00	22.00	8.00	19.00	6.00	15.00	12.00	26.00	19.00	61.00	158	166	18.00	21.00	16.00	23.00	11.00	23.00	24.00	26.00
Inventory	-16.9%	6.00	7.00	7.00	9.00	9.00	8.00	9.00	8.00	9.00	9.00	12.00	13.00	11.00	10.00	11.00	11.00	10.00	11.00	14.00	20.00	15.00
Net PPE	-3.7%	9.00	9.00	9.00	9.00	9.00	10.00	9.00	9.00	10.00	11.00	10.00	10.00	9.00	10.00	9.00	7.00	6.00	5.00	5.00	6.00	6.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	80.00	80.00
Liabilities	8.3%	28.00	26.00	23.00	17.00	17.00	16.00	16.00	16.00	16.00	17.00	18.00	16.00	18.00	17.00	18.00	16.00	17.00	19.00	34.00	72.00	70.00
Current Liabilities	52.7%	19.00	13.00	12.00	11.00	11.00	10.00	10.00	10.00	9.00	10.00	9.00	8.00	10.00	10.00	12.00	10.00	13.00	13.00	12.00	23.00	20.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	2.00	3.00	3.00	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	1.00	0.00	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	2.00	3.00	-	-	-	-	-	-
Shareholder's Equity	-61.0%	13.00	33.00	47.00	62.00	80.00	100	113	131	151	169	182	196	206	62.00	62.00	60.00	67.00	56.00	64.00	131	147
Retained Earnings	-2.4%	-961	-939	-922	-903	-883	-860	-843	-824	-804	-785	-769	-753	-740	-722	-709	-694	-680	-663	-649	-552	-531
Additional Paid-In Capital	0.3%	976	973	971	966	964	963	961	959	957	955	950	947	945	781	770	755	750	720	716	683	679
Shares Outstanding	2.7%	272	265	264	240	239	237	236	237	236	235	224	234	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	120	-	-	-	93.00	-	-	-	732	-	-	-	29.00	-	-	-	245	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-4.7%	-14,008	-13,374	-15,049	-17,956	-17,248	-14,053	-14,654	-14,287	-15,943	-13,172	-9,002	-8,248	-10,237	-12,765	-8,774	-12,659	-12,477	-14,368	-19,578	-15,343	-24,195
Share Based Compensation	-13.0%	1,745	2,005	2,019	1,978	1,916	2,055	2,033	2,083	2,245	2,840	2,961	1,842	1,786	2,111	1,944	1,933	1,923	1,781	3,391	3,355	2,981
Cashflow From Investing	-59.6%	3,000	7,427	20,778	6,564	29,737	6,327	18,037	128	23,045	-30,598	-88,370	-305	-395	-	-	-1.00	-2.00	15,920	9,797	12,940	28,988
Cashflow From Financing	371.5%	811	172	9,743	194	-483	-	-1.00	5.00	-336	1,564	33.00	503	159,605	8,936	13,649	6,081	24,704	-14,344	8,730	268	-263

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ASXC Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Revenue	$ 1,123	$ 976
Cost of revenue:
Cost of revenue	3,056	2,947
Gross loss	(1,933)	(1,971)
Operating Expenses:
Research and development	8,091	10,139
Sales and marketing	3,642	4,553
General and administrative	4,374	5,468
Amortization of intangible assets	114	112
Change in fair value of contingent consideration	6,480	105
Total operating expenses	22,701	20,377
Operating loss	(24,634)	(22,348)
Other income (expenses), net
Change in fair value of warrant liabilities	2,116	0
Interest income	126	439
Other expense, net	(59)	(218)
Total other income (expense), net	2,183	221
Loss before income taxes	(22,451)	(22,127)
Income tax expense	(46)	(91)
Net loss	$ (22,497)	$ (22,218)
Net loss per common share attributable to common stockholders - basic and diluted (in dollars per share)	$ (0.08)	$ (0.09)
Weighted average number of shares used in computing net loss per common share - basic and diluted (in shares)	269,265	238,280
Comprehensive loss:
Net loss	$ (22,497)	$ (22,218)
Foreign currency translation (loss) gain	(494)	550
Unrealized gain on available-for-sale investments	8	307
Comprehensive loss	(22,983)	(21,361)
Product [Member]
Revenue:
Revenue	313	293
Cost of revenue:
Cost of revenue	1,681	1,225
Service [Member]
Revenue:
Revenue	285	195
Cost of revenue:
Cost of revenue	452	749
Lease [Member]
Revenue:
Revenue	525	488
Cost of revenue:
Cost of revenue	$ 923	$ 973

ASXC Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 6,995	$ 17,096
Short-term investments, available-for-sale	994	3,971
Accounts receivable, net	675	3,508
Inventories	5,958	7,172
Prepaid expenses	3,314	3,143
Other current assets	1,312	1,496
Total Current Assets	19,248	36,386
Restricted cash	1,483	1,642
Inventories, net of current portion	3,954	4,043
Property and equipment, net	8,630	8,959
Intellectual property, net	1,114	1,237
Net deferred tax assets	37	44
Operating lease right-of-use assets, net	4,926	5,165
Other long-term assets	1,422	1,610
Total Assets	40,814	59,086
Current Liabilities:
Accounts payable	4,036	4,145
Accrued employee compensation and benefits	3,814	5,390
Accrued expenses and other current liabilities	1,243	1,636
Contingent consideration, current	8,700	0
Operating lease liabilities, current	1,056	1,036
Deferred revenue	439	421
Total Current Liabilities	19,288	12,628
Long-Term Liabilities:
Deferred revenue - less current portion	330	290
Contingent consideration	0	2,220
Warrant liabilities	3,772	5,888
Noncurrent operating lease liabilities	4,400	4,646
Total Liabilities	27,790	25,672
Commitments and Contingencies
Stockholders' Equity:
Common stock $0.001 par value, 750,000,000 shares authorized at March 31, 2024 and December 31, 2023; 271,986,369 and 264,921,526 issued and outstanding at March 31, 2024 and December 31, 2023, respectively	272	265
Preferred stock, $0.01 par value, 25,000,000 shares authorized, no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Additional paid-in capital	975,715	973,129
Accumulated deficit	(961,865)	(939,368)
Accumulated other comprehensive loss	(1,098)	(612)
Total Stockholders' Equity	13,024	33,414
Total Liabilities and Stockholders' Equity	40,814	59,086
Intellectual Property [Member]
Current Assets:
Intellectual property, net	$ 1,114	$ 1,237

About Asensus Surgical, Inc.

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

CEO	Mr. Anthony Fernando
WEBSITE	asensus.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	183

Asensus Surgical, Inc. Frequently Asked Questions

What is the ticker symbol for Asensus Surgical, Inc.? What does ASXC stand for in stocks?

ASXC is the stock ticker symbol of Asensus Surgical, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Asensus Surgical, Inc. (ASXC)?

As of Fri May 17 2024, market cap of Asensus Surgical, Inc. is 70.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ASXC stock?

You can check ASXC's fair value in chart for subscribers.

What is the fair value of ASXC stock?

You can check ASXC's fair value in chart for subscribers. The fair value of Asensus Surgical, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Asensus Surgical, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ASXC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Asensus Surgical, Inc. a good stock to buy?

The fair value guage provides a quick view whether ASXC is over valued or under valued. Whether Asensus Surgical, Inc. is cheap or expensive depends on the assumptions which impact Asensus Surgical, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ASXC.

What is Asensus Surgical, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ASXC's PE ratio (Price to Earnings) is -0.9 and Price to Sales (PS) ratio is 8.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ASXC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Asensus Surgical, Inc.'s stock?

In the past 10 years, Asensus Surgical, Inc. has provided -0.394 (multiply by 100 for percentage) rate of return.